Online ISSN: 2515-8260

Keywords : Silodosin

Comparison of Silodosin and Dapoxetine in “on-demand” treatment of Premature ejaculation:A randomized controlled study

Dr. Shiv Shankar Sharma,Dr. Shivam Priyadarshi, Dr. Nachiket Vyas, Dr.S. S. Yadav, Dr. Govind Sharma

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 2819-2823

Aim: To compare Silodosin and Dapoxetine in the “on-demand” treatment of premature ejaculation.
Material and method: The study was conducted in the department of urology and renal transplant S.M.S. Medical College Jaipur from 1st January 2018 to 31st December 2018. We enrolled 90 self-reported casesof PME and excluded the patients below 18 years and above 50 years; patients suffering from orthostatic hypotension, renal impairment, and hepatic impairment. All patients were divided equally into three groups by a simple randomization method using computer-generated random numbers i.e.,Group A(Silodosin 4 mg on-demand), Group B (Dapoxetine 30 mg on-demand), and Group C (placebo on demand). Intravaginal ejaculatory latency time (IELT), premature ejaculation profile (PEP), and the clinical global impression of change for premature ejaculation (CGIC) were recorded in patients, before the initiation of the treatment and after ten coital activities or after one month. Any adverse effects reported by the patients were also recorded.
Results: There was a significant improvement in intravaginal ejaculation latency time in both Silodosin and Dapoxetine groups. Patients of group A and group B reported better scores in all aspects of premature ejaculation profile as compared to placebo. Only three patients reported a reduced amount of ejaculate with silodosin but it was not bothersome to patients.
Conclusion: Silodosin 4 mg may be used safely as a treatment option for PME as its safety profile in LUTS is already well established. It is as effective as Dapoxetine 30 mg with a better side effect profile in the management of premature ejaculation.

Urolithiasis Updated Management Guidelines in Lower Ureters

Mohamad Omar Al Farouk Zaitoun, Lotfy Abd El-Latif Bendary, Diab El-Sayed Mohamed Ibrahim, Mohamed Ahmed Kamel Omran

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 4383-4391

Background: Urinary calculi are one of the most common diseases of the urinary tract. The
prevalence rate has gradually increasedto 20% in recent decade. Medical expulsive therapy
(MET) has been discussed as a conservative treatment option in the management of distal
ureteral stones. Medical management therapy including alpha-blockers, calcium channel
blockers and phosphodiestrase5 (PDE5) inhibitors have been described. Stone passage through
the ureter is dependent on stone diameter and ureteral condition. In addition to ureteral spasm,
edema is an important factor in arresting ureteral stone passage. Alpha-blockers can inhibit
ureteral muscle contraction, reduce basal muscle tone and reduce peristaltic rate. The alpha-1
adrenergic blockers are most common used agents for MET. Silodosin may increase the rate of
stone expulsion rate and decrease the expulsion time.

C-reactive protein: A reliable parameter to predict the success of medical expulsive therapy using silodosin in small distal ureteric calculus

Dr.NandakishoreB, Dr.Suyog Shetty, Dr.Imdad Ali, Dr.Ravishankar THS

European Journal of Molecular & Clinical Medicine, 2018, Volume 5, Issue 1, Pages 356-361

Background: Plasma C-Reactive Protein (CRP) is an acute-phase protein whose serum level increases in response to inflammation, as happens in impacted ureteric calculus. Few studies have investigated the efficacy of silodosin, a selective alpha 1-A adrenoceptor antagonist, in medical expulsive therapy (MET) for distal ureteral calculi. The studies showed the efficacy of silodosin 8 mg/day as a potential treatment for distal ureteric calculus expulsion. In this study wedetermined the correlation of CRP Levels at the starting of MET and the success of METwith SILODOSIN after 3 weeks. Materials and Methods: 70 patients with distal ureteric calculus between 5-9 mm size were included in this study. They were divided into 2 groups based on the initial CRP level at the time of first presentation to the hospital.CRP level of 6mg/L was taken as cut-off. Group 1 with 35 patients having CRP value morethan 6and Group 2 with 35 patients having CRP value of less than 6.